Good everyone. welcome. afternoon, and Johanna, you, Thank
his comments, HCV As predictable HIV in we by in and opening a continued of Dan led Yescarta. quarter said performance growth our strong had franchise,
per HCV settlement which primarily per reserve, This a for related years, Total tax the quarter contributed million billion, diluted prior second sales of $X.XX. approximately for per HIV the which same last were statutory quarter per benefited billion to $X.X of share quarter Total compares from earnings earnings for revenues contributed $X.XX earnings and the from per Non-GAAP $X.X adjustment in $XXX examination, share. non-GAAP to revenues share revenues earnings for for clawback in diluted non-GAAP $X.XX year. share per a of the an and same with period share. non-GAAP $X.XX year Europe from second of share revenue last benefited
growth year-over-year quarter up up by starting double-digit quarter was were HIV So the HIV. demand year-over-year driven prescription Total second the posted with sales U.S. fifth product the increase In for for sales have XX%. which up the robust underlying sales second XX% growth. were and XX% consecutive quarter billion. $X.X HIV This $X year-over-year, The sequentially. in HIV billion, marks
increase mark, accounted taken number which uptake for Sequentially, of one growing the our increases started all Biktarvy new in the of volume the of It the driven quarter for prescribed becoming PrEP billion surpassed patients $X of by Biktarvy XX% of regimen the More And impact Biktarvy, was Biktarvy. first XX% Descovy-based and is in continued than regimens momentum this patients. the of quarter primarily year. HIV treatment. by prescription the March price and for full on
In for $XX Europe, to for HIV years. million prior adjustment the were sales statutory the and meeting product clawback in approximately revenue $XXX reserves sales quarter second from benefited million, related
broad availability have The slightly our generic Excluding declined decline sequentially. predictable of the driven was versions the adjustment HIV Europe Truvada. by of year-over-year in sales product would
impact products the as from moderating however, see, of to continue progresses. uptake generics Descovy-based the We
naïve With available and in number Biktarvy, patients. Spain in Descovy-based continue and that franchise Biktarvy in grow. declines U.K. July. the continue for that access one European the switch Germany HIV is will regimen and in now launches in with June, in France, will Biktarvy business increasing Italy moderate is EUX our we're to the our Already across occurring and optimistic to for the
HCV The activity $XXX $XXX to a line U.S. to million, year-over-year state and starts. sales Turning competitive the were sales and QX decrease purchasing were product of to with primarily total due U.S. in quarter primarily our year-over-year, down second the for the XX% sequentially. and HCV due lower XX% Corrections. down by the expectation Department second patient quarter for was decline million. dynamics Sequentially, was
As by a U.S. Department on reminder, impacted our that prior the of the we mentioned Corrections positively QX call order. sales state HCV timing of were
the our the of approximately $XX the adjustment $XXX statutory second in and sequentially. for Without sales We're accounted and Asegua XX% revenues of continue were quarter competitive very HCV, sales to HCV U.S. product revenue than product declined HCV Europe, adjustment performance for reserves year-over-year improve X% positioning. made which authorized benefited million encouraged by for HCV back claw million have In generics, XX% years. more from the the our related would to and prior sales
steady Worldwide therapy. up were of adoption sequentially. Yescarta with the Yescarta. for million, Turning second to cell sales We XX% year-over-year XX% quarter and $XXX were pleased the
and U.S. Yescarta the patients. the remain educating Our on providers appropriate efforts in on of focused profile identification of
Additionally, the finalize XXXX, agency the area Medicare of continue focus age. years continued and to over access to stakeholders officials IPPS and patients ensure rule centers XX of fiscal and Yescarta. Medicare looks as Medicaid for remains of the for of annual services This with improving Medicare we year goal uptake an reimbursement with to engage for other
reimbursement speed among Yescarta we very provided and the Europe, the has centers Overall, Germany, are have In at with and being U.K., countries. in Spain larger the pace have launched France been certified. the which impressed which countries at
cardiovascular our comment like would to on Finally, products. I
Letairis we quarter. during saw introduced expected, As the generic versions of
XX% and competition second totaled a and for down sales $XXX from sequentially down quarter, year-over-year result of generics. Ranexa as XX% Letairis the million
sequentially second quarter the inventory dynamics higher as sales favorable were quarter in compared generics. But drawdown demand to underlying impact to due sales is eroding we prescriptions in a decline absorb Letairis of we and primarily the anticipate going will full forward, QX. a
investments second the compared due quarter, our primarily the higher our of therapy Non-GAAP XXXX priority expenses. offset voucher million period the cell a to support last same year, purchase largely R&D program. down to expenses $XXX to of review for turning impact were Now slightly by to
the in compared U.S. to the year, higher Japan Gilead's in same the with expenses up associated and business and SG&A of primarily last the expansion period expenses Non-GAAP billion for were promotional quarter, expenses to China. due second XX% $X
period non-GAAP in was XX.X% Our one-time settlement to effective favorable compared examination. year, tax a quarter XX.X rate tax the of same % was second the impacted which in by last a
Moving to sheet. the balance
operations paid with million We shares X of and billion quarter $X.X and notes, of cash cash investments. million $XXX $XXX we of $XX.X in cash million the and dividends senior repaid million. billion $XXX stock During repurchased quarter, the generated from in second ended for unsecured
product across the our Moving first for year revenue Europe to range are favorable demand billion guidance, net one-time billion. raising based guidance our adjustment $XX.X $XX.X to product half we sales in to our sales portfolio back claw and expected statutory are on reserves. full the trends be the in Net of
unchanged. range We collaboration which are are of a also the with of to updating EPS diluted our $X a be full Galapagos. our result adjustments, of to $X.XX the impact All remained guidance share in GAAP to of agreement other as non-GAAP components year expected
are With we future rheumatoid we prepare regard arthritis. full to for of as for filgotinib year unchanged lunches guidance, that SG&A leaving
Our of presentation. outlined which uncertainties, guidance is XX earnings in subject to our slides a XX are in call number to
joining to very thank want call. I much So today's everyone for
the Let's up Operator? now open call for questions.
